Highlights

  • Public offerings of 45.86M shares priced at USD 2.90 per share, rising roughly USD 135M.
  • Pre-funded warrants issued for up to 700,000 shares at USD 2.899 per warrant.
  • Proceeds intended to fund pivotal Phase 3 development and general corporate purposes.

X4 Pharmaceuticals (NASDAQ:XFOR) announced the pricing of its underwritten public offering of 45,860,000 shares of common stock at USD 2.90 per share. The company also issued pre-funded warrants allowing certain investors to purchase up to 700,000 shares at USD 2.899 per warrant. These warrants have an exercise price of USD 0.001 per share and are exercisable immediately.

The offering is expected to generate approximately USD 135M in gross proceeds, before deducting underwriting discounts, commissions, and other offering expenses.

Planned Use of Proceeds

X4 intends to use the net proceeds from the offering, along with existing cash, cash equivalents, and cash generated from operations, to support the pivotal Phase 3 development of mavorixafor for certain chronic neutropenic disorders. Additional uses include general and administrative expenses, capital expenditures, working capital, and other corporate purposes.

About X4 Pharmaceuticals

X4 Pharmaceuticals develop treatments for rare hematological diseases. Its lead product, mavorixafor, is an orally administered CXCR4 antagonist marketed in the U.S. as XOLREMDI® for its initial indication. The company is conducting a global pivotal Phase 3 trial (4WARD) for patients with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts.